

## 4th Quarter 2025 Injectable Medication HCPCS/DOFR Crosswalk

### Use the updates for dates of service on and after March 10, 2026

The Pharmacy Advisory Committee approved updates to the Injectable Medication HCPCS/Division of Financial Responsibility (DOFR) Crosswalk on November 25, 2025. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, **effective March 10, 2026**, are listed on pages 2–6 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net\* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- 21 **new injectable** medications to be added to the crosswalk
- 21 **updates and changes** to current injectable medication procedure codes
- 8 **new biosimilars** and updates to be added to the crosswalk
- 7 **new** generic drugs
- 3 **category** changes

#### Need help? Contact us

Relevant sections of the Plan's provider operations manuals will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) > *Provider Library under Quick Links*, or go directly to [providerlibrary.healthnetcalifornia.com](https://providerlibrary.healthnetcalifornia.com).

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

#### THIS UPDATE APPLIES TO:

- Participating Physician Groups

#### PROVIDER SERVICES

CalViva Health Medi-Cal  
(including ECM and CS providers) –  
888-893-1569

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com)

## New injectable medications to be added to the Injectable Medication HCPCS/DOFR Crosswalk

The following medications have been approved as additions to the crosswalk reference table.

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
90288	BabyBIG®	Botulism immune globulin, human, for intravenous use	Therapeutic injection	
90287	Botulism antitoxin heptavalent	Botulinum antitoxin, equine, any route	Therapeutic injection	
J9999	Blenrep®	Belantamab mafodotin-blmf for intravenous (IV) solution, 70 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
J3490	Brekiya®	Dihydroergotamine mesylate solution auto-injector, 1 mg/mL	Self-injectable	
J0577	Brixadi® weekly	Injection, buprenorphine extended-release, less than or equal to 7 days of therapy	Therapeutic injection	
J3490	Dawnzera™	Donidalorsen sodium subcutaneous solution auto-injector, 80 mg/0.8 mL	Self-injectable	
J7177	Fibryga®	Fibrinogen concentrate (human) for IV solution, 2 gm	Therapeutic injection	
J3490	Forzinity™	Elamipretide HCL subcutaneous solution, 280 mg/3.5 mL	Self-injectable	
J1612	Gvoke®	Injection, glucagon, 0.01 mg	Self-injectable	
90371	Hyperhep B®	Hepatitis B immune globulin (HBIG), human, for intramuscular use	Therapeutic injection	
C9399	Keytruda QLEX™	Pembrolizumab-berahyaluron-pmph injection	Therapeutic injection	Chemotherapy <sup>1</sup>
J3490	Leqembi® IQLK™	Lecanemab-irmb solution auto-injector, 360 mg/1.8 mL	Self-injectable	
91304	Nuvaxovid™	COVID-19 vaccine, adjuvanted	Therapeutic injection	Immunization
J3590	Papzimeos™	Zopapogene imadenovec-drba	Therapeutic injection	
90384	RhoGAM® ultra-filtered plus	Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use	Therapeutic injection	
91322	Spikevax®	COVID-19 vaccine, mRNA	Therapeutic injection	Immunization

**New injectable medications to be added to the Injectable Medication HCPCS/DOFR Crosswalk,**  
*continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
<b>J3590</b>	Yimmugo®	Immune Globulin (Human)-dira IV solution, 10 gm/100 mL	Therapeutic injection	
<b>J3490</b>	Zurnai™	Nalmefene HCl solution auto-injector, 1.5 mg/0.5 mL (base equivalent)	Self-injectable	
<b>J3490</b>	Zegalogue®	Dasiglucagon injection, for subcutaneous use	Self-injectable	
<b>J0681</b>	Zevtera®	Injection, ceftobiprole medocartil sodium, 3 mg	Therapeutic injection	Home health/infusion <sup>2</sup>
<b>J0668</b>	Zynrelef®	Bupivacaine and meloxicam extended-release solution	Therapeutic injection	

**Updates/changes to current injectable medication procedure codes or HCPCS codes**

Updates to the Injectable Medication HCPCS/DOFR Crosswalk are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk reference table.

HCPCS	Drug name	Generic name	Comment
<b>J9215</b>	Alferon N®	Interferon alfa-N3 (human leukocyte derived), 250,000 IU injection	No longer manufactured
<b>J0457</b>	Azactam®	Injection, aztreonam, 100 mg	Replaces S0073
<b>J0515</b>	Benztropine	Benztropine (brand name, formerly, Cogentin®) mesylate injection, 1 mg	The brand-name Cogentin has been discontinued
<b>J3490</b>	Bydureon®	Exenatide extended release	No longer manufactured
<b>J3490</b>	Bydureon® BCise	Exenatide extended release injectable suspension, 2 mg	No longer manufactured
<b>J0636</b>	Calcijex®	Injection, calcitriol, 0.1 mcg	Brand has been discontinued; a generic version is available
<b>91320</b>	Comirnaty® 2024-2025	Covid-19 Vaccine, mRNA, 24-25 Formula	No longer manufactured
<b>J0802</b>	Cortrophin gel	Injection, corticotropin (animal-based), up to 40 units	Additional manufacturer
<b>J0759</b>	Cleviprex®	Clevidipine butyrate, 1 mg	Replaces C9248

**Updates/changes to current injectable medication procedure codes or HCPCS codes, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Comment</b>
<b>C9306</b>	Emrelis™	Telisotuzumab vedotin-tllv for injection, for IV use	Replaces J9999
<b>J3403</b>	Encelto™	Revakinagene taroretcel-lwey intravitreal implant 200,000 cells	Replaces J3402
<b>J0139</b>	Humira® (2 pen)	Injection, adalimumab, 1 mg	Code added
<b>J0641</b>	Fusilev®	Levoleucovorin calcium, 0.5 mg	Brand has been discontinued; a generic version is available
<b>C9305</b>	Imaavy™	Nipocalimab-Aahu IV solution	Replaces J3590
<b>J9065</b>	Leustatin®	Cladribine per 1 mg	No longer manufactured
<b>J3490</b>	Lusedra®	Fospropofol disodium Injection	No longer manufactured
<b>J2151</b>	Mannitol	Mannitol injection	Replaces J2150
<b>J7174</b>	Qfitlia™	Fitusiran injection, for subcutaneous use	Replaces J3490
<b>J0900</b>	Valertest #1	Testosterone enanthate and estradiol valerate	No longer manufactured
<b>90625</b>	Vaxchora®	Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use	This oral suspension will be discontinued
<b>J0740</b>	Vistide®	Cidofovir, 375 mg injection	Brand has been discontinued; a generic version is available

**New biosimilars added to the Injectable Medication HCPCS/DOFR Crosswalk**

The following medications have been approved as additions to the crosswalk reference table.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J3590</b>	Bilprevda®	Denosumab-nxxp injection, for subcutaneous use biosimilar to Xgeva®	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>
<b>J3590</b>	Bildyos®	Denosumab-nxxp injection, for subcutaneous use biosimilar to Prolia®	Therapeutic injection	
<b>J3590</b>	Jobevne™	Bevacizumab-nwgd, biosimilar to Avastin®	Therapeutic injection	

**New biosimilars added to the Injectable Medication HCPCS/DOFR Crosswalk , *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>Q5134</b>	Tyruko®	Natalizumab-sztnm, biosimilar to TYSABRI®	Therapeutic injection	
<b>J3590</b>	Starjemza™	Ustekinumab-hmny IV solution, 130 mg/26 mL (5 mg/mL) (for IV infusion), biosimilar to Stelara®	Therapeutic injection	
<b>J3590</b>	Starjemza™	Ustekinumab-hmny solution prefilled syringe, 45 mg/0.5 mL, biosimilar to Stelara	Self-injectable	
<b>J3590</b>	Starjemza™	Ustekinumab-hmny subcutaneous solution, 45 mg/0.5 mL, biosimilar to Stelara	Self-injectable	

**New generic injectable medications**

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J0163</b>	Epinephrine	Injection, epinephrine in sodium chloride (endovenous administration), 0.1 mg	Therapeutic injection	
<b>J0164</b>	Epinephrine	Injection, epinephrine in sodium chloride (Baxter), 0.1 mg	Therapeutic injection	
<b>J0462</b>	Atropine sulfate	Injection, atropine sulfate, not therapeutically equivalent to J0461, 0.01 mg	Therapeutic injection	
<b>J0675</b>	Carboprost	Injection, carboprost tromethamine, 0.1 mg	Therapeutic injection	
<b>J1370</b>	Esomeprazole sodium	Injection, esomeprazole sodium, 1 mg	Therapeutic injection	
<b>J2290</b>	Nafcillin	Injection, nafcillin sodium, 20 mg	Therapeutic injection	Home health/infusion <sup>2</sup>
<b>J0582</b>	Bivalirudin	Injection, bivalirudin (endovenous administration), not therapeutically equivalent to J0583, 1 mg	Therapeutic injection	

---

## Category changes

The following medications have been approved to correct the secondary category listed below.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J3490</b>	Saxenda®	Liraglutide (weight management) solution pen-injector, 6 mg/mL	Self-injectable	
<b>J3490</b>	Victoza®	Liraglutide [rDNA origin] injection	Self-injectable	
<b>J3490</b>	Saxenda®	Liraglutide (weight management) solution pen-injector, 6 mg/mL	Self-injectable	

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

<sup>2</sup>When administered by a nurse in a home setting.

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at [www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/alpha-numeric](http://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/alpha-numeric).